" /> KRAS G12D Inhibitor MRTX1133 - CISMeF





Preferred Label : KRAS G12D Inhibitor MRTX1133;

NCIt synonyms : KRAS-G12D Inhibitor MRTX1133;

NCIt related terms : MRTX-1133;

NCIt definition : An orally bioavailable reversible inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, KRAS G12D inhibitor MRTX1133 specifically targets and noncovalently binds to KRAS G12D. This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This leads to an inhibition of the growth of tumor cells that overexpress KRAS G12D. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.;

UNII : DU32DM9CHD;

CAS number : 2621928-55-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2621928-55-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : MRTX 1133; MRTX1133; MRTX -133;

NCI Metathesaurus CUI : CL1907132;

Details


You can consult :


Nous contacter.
09/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.